Deutsche Bank Comments on How Biogen Idec May be Affected by Tecfidera IMS Data

In a report published Friday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating and $340.00 price target on Biogen Idec (NASDAQ: BIIB ). In the report, Deutsche Bank noted, “Our calculations on IMS data for Tecfidera for week ending 11/22 indicate strong Tecfidera at $363M-$365M in Q4'13. For FY